Cyagen delivers a full-service partnership that extends from study design to data interpretation:

Dedicated Ph.D. project manager and technical specialists for real-time progress updates

In-house downstream services – histopathology, flow cytometry, multi-omics (RNA-Seq, proteomics), in vivo imaging, and drug-efficacy testing

Custom assay development & data analysis – tailored to immuno-oncology endpoints

Regulatory-ready documentation – health certificates, QC reports, and SOPs compatible with GLP submissions

This integrated support enables researchers to accelerate discovery while relying on Cyagen for model generation, colony management, and comprehensive phenotyping under one roof.

Our QC framework combines:

Genotype confirmation – PCR/long-range PCR, Sanger sequencing, and copy-number checks for each founder and every breeding generation.

Microbiological surveillance – SPF housing, quarterly sentinel panels, and mycoplasma/fecal PCR screens.

Environmental controls – IVC/EVC caging, HEPA-filtered airflow, and automated temperature/humidity logging.

Comprehensive records – digital pedigree tracking and colony health logs accessible to clients upon request.

These multilayer safeguards minimize drift, adventitious infection, and phenotypic variability.

The turnaround time for custom spontaneous tumor model generation is determined after project-specific design evaluation. Timeline may vary depending on the target gene, mutation type, strain background, breeding strategy, and required validation scope.
Cyagen’s scientific team will provide a tailored generation plan and estimated timeline after reviewing the project requirements. For qualified custom model projects, Cyagen offers germline transmission support and will continue the necessary breeding, screening, or re-generation steps according to the agreed project scope until a GLT-positive line is obtained.

Yes. Cyagen’s spontaneous-tumor portfolio includes KRAS-driven PDAC strains such as LSL-Kras G12D/G12C mice and allied Cre-driver combinations. These models reproduce hallmark oncogenic mutations (e.g., KRAS-G12D, G12C) and develop in-situ tumors within an intact, immunocompetent C57BL/6 microenvironment—capturing the dense stroma and immune contexture characteristic of human PDAC. Custom syngeneic or multi-allelic PDAC models can also be generated on request.

Absolutely. Each catalogued spontaneous tumor line is delivered with a data package that typically includes survival curves, gross-pathology images, H&E/IHC staining, and, where available, transcriptomic readouts. For example, our MYC-driven liver tumor model page shows survival data and histopathology images that validate tumor onset and progression. Additional assays (flow cytometry, RNA-Seq, etc.) can be commissioned through our in-house phenotype analysis platform.

Yes, several specialized preclinical oncology CRO companies provide dedicated platforms for cancer research. Cyagen is a premier provider in this space, offering a comprehensive suite of oncology CRO services designed to bridge the gap between discovery and clinical success.

Unlike generalist providers, Cyagen specializes in high-fidelity tumor modeling and advanced therapeutic evaluations, featuring:

• Diverse Model Portfolios: Access to an extensive library of CDX, PDX, Syngeneic, and humanized GEMMs.


• Deep Scientific Expertise: Support for cutting-edge modalities including cell and gene therapies (CGT), mRNA vaccines, and bispecific antibodies.


• Proven Track Record: With over 200 rigorous internal characterizations and a history of supporting successful IND applications, we provide the reliable data necessary to accelerate your oncology pipeline.